Slides
Page 2
Disclaimer 2 Forward-Looking Statements This presentation contains forward-looking statements, which involve numerous risks and uncertainties. Included are statements relating to opening of new clinics, availability of personnel and reimbursement environment. The forward-looking statements are based on the Company’s current views and assumptions and the Company’s actual results could differ materially from those anticipated as a result of certain risks, uncertainties, and factors, which include, but are not limited to: changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status; revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction; changes in reimbursement rates or payment methods from third party payorsincluding government agencies, and changes in the deductibles and co-pays owed by patients; private third-party payors for our services may adopt payment policies that could limit our future revenue and profitability; compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply; compliance with state laws and regulations relating to the corporate practice of medicine and fee splitting, and associated fines and penalties for failure to comply; competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwilland other intangible assets; the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants; certain of our acquisition agreements contain put-rights related toa future purchase of significant equity interests in our subsidiaries or in a separate company; the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations; our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business; changes as the result of government enacted national healthcare reform; the ability to control variable interest entities for which we do not have a direct ownership; business and regulatory conditions including federal and state regulations; governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions orreputational harm and increased costs; revenue and earnings expectations; contingent consideration provisions in certain of our acquisition agreements, the value of which may impact future financial results; legal actions, which could subject us to increased operating costs and uninsured liabilities; general economic conditions, including but not limited to inflationary and recessionary periods; actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the U.S or the international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations; our business depends on hiring, training, and retaining qualified employees; availability and cost of qualified physical therapists; competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line; our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses; impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests); maintaining our information technology systems with adequate safeguards to protect against cyber-attacks; a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of1996 of the Health Information Technology for Economic and Clinical Health Act; maintaining clients for which we perform management, industrial injury prevention relatedservices, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected; maintaining adequate internal controls; maintaining necessary insurance coverage; availability, terms, and use of capital; and weather and other seasonal factors. See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, and any subsequent filings we make with the SEC. Non-GAAP Financial Measures This Presentation includes certain measures (“non-GAAP financial measures”) which are not presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), such as Operating Results, basic and diluted Operating Results per share, Adjusted EBITDA, Adjusted EBITDA margin and other Non- GAAP measures. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP andmay exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation oras an alternative to GAAP measures. Our presentation of these measures may not be comparable to similarly titled measures used by other companies. Management believes that such measures are commonly reported by issuers and widely used by investors as indicators of a company’s operating performance. All non-GAAP financial measures contained herein should be considered only as a supplement to, and not as a superior measure to, financial measures prepared in accordance with GAAP.
Page 3
779 Owned/Managed Outpatient Physical and Occupational Therapy Clinics (1) 44 State National Footprint (1) 85% Physical Therapy Operations % of Revenue (1) 15% Injury Prevention Services % of Revenue (1) >$40bn US Rehabilitation Market >10% No Company Has Greater Than 10% Market Share (3) Partner of Choice with Experienced Physical Therapists $759mm TTM Revenues (2) $92mm TTM Adj EBITDA (2)(4) 18% YoY Revenue Growth (1) $1.80 Annual Dividend Proven Business Model Attractive Market Dynamics Leading Physical Therapy Company USPh At a Glance Strong Financial Position • One of the largest PT clinic owner/operator platforms in a highly fragmented market • Leading public physical therapy platform • Headquarters: Houston, TX • Founded: 1990 • Employees: 7,000+ Favorable Demographic Trends (1) As of or for the nine months ended September 30, 2 025, compared to the nine months ended September 30, 2024. Included in the clinic count shown above are 34 clinics that the Company manages on behalf of third parties. (2) For the trailing twelve months ended September 30, 2025. (3) Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT). Select Medical use d as proxy for largest physical therapy operator in the U. S. with 1,944 outpatient rehabilitation clinics as of Sept 30, 2023. (4) Adjusted EBITDA is a non-GAAP financial measure and has not been prepared in accordance with GAAP. See Recon ciliation of Non-GAAP Financial Measures - Adjusted EBITDA for further detail. Driven by Organic Growth and Acquisitions Diversified Payor Mix 3
Page 4
Expanding National Footprint of Physical Therapy Clinics 4 * Included in the clinic count (but excluded from the map) are 34 clinics that the Company manages on behalf of third parties.
Page 5
Large and Growing Market Opportunity 5 $40B+ U.S. rehab market Favorable demographics – physically active, aging and obese population segments Significant market potential ~50% of Americans over 18 years old develop a musculoskeletal injury that lasts more than 3 months Within this group, only 10% use outpatient physical therapy services (1) Healthcare delivery shifting towards lower cost, high quality outpatient providers Operating environment favors market consolidators with scale (1) Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT), Market Research.
Page 6
Outpatient Clinics are the Leading Setting For Care 6 Orthopedic rehab is the primary driver of physical therapy services, representing approximately 60% of visits Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT). 42% 28% 12% 7% 11% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Outpatient Clinics Hospitals; State, Local, and Private Home Health Offices of Physicians Other Physical Therapy Delivery Mix
Page 7
Payors See Significant ROI for Physical Therapy 7 Total Treatment Cost ~$79K Hip replacement surgery ($56,000) Inpatient care ($15,000) Total Treatment Cost ~$85K Hip replacement surgery ($56,000) Inpatient care ($15,000) Readmission Rate of 20% Readmission Rate of 10% Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT). Outpatient Physical Therapy Clinic Full Recovery Home Full Recovery With PT Without PT Average overall savings of ~$6k with significantly lower readmission rate
Page 8
Competitive Landscape 8 (1) Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT). (2) Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT). Select Medical use d as proxy for largest physical therapy operator in the U.S. with 1,925 outpatient rehabilitation clinics as of September 30, 2024. (3) Clinic counts as of September 30, 2025. (4) Clinic count as of December 31, 2024. 1,900+ Clinics (3) 1,900+ Clinics (3) 850+ Clinics (4) 850+ Clinics (4) 779 Managed / Owned Clinics (3) 779 Managed / Owned Clinics (3) Highly fragmented U.S. outpatient rehab market with 37,000+ clinics (1) Highly fragmented U.S. outpatient rehab market with 37,000+ clinics (1) USPh is one of the largest owner/operator of PT clinics USPh is one of the largest owner/operator of PT clinics No company with >10% market share (2) No company with >10% market share (2) USPh is well-positioned to capitalize in a more challenged macro environment USPh is well-positioned to capitalize in a more challenged macro environment
Page 9
Physical Therapy Growth Strategy 9 Drive organic growth through de novo PT/OT clinic openings (utilize true partnership model) Maximize profits of existing facilities by growing volume, improving pricing, increasing efficiencies and adding programs and services Augment organic growth through strategic acquisitions of PT / OT practices 1 2 3
Page 10
Highly Retentive, Partnership Model 10 Specialize in trauma, sports, work-related and pre- and post-surgical cases Partner with experienced physical therapists Drive volume via referrals Augment sales with marketing reps Organic growth includes lower cost de novo start up clinics Strategic acquisitions structured as partnerships to create strong alignment of interests: Significant ownership retained by founders (~20% to 50%) Maintain established local brand Monthly distributions of cash generated based on ownership percentages Agree to purchase remaining interest of partners on back end at typically the same EBITDA multiple as the original purchase
Page 11
USPh Partnership Advantages 11 Accounting HR Real Estate Construction Purchasing Contracting/Credentialing Marketing Compliance Legal IT Capital and Resources to Enhance Development Rate No Personal Financial Risk Aligned Practice Incentives Unlimited Earnings Potential Enhanced Benefits Package Business Intelligence and Collaborative Guidance
Page 12
Acquisition Strategy 12 Completed more than 50 acquisitions since 2005 ranging in size from 1 to 52 clinics Acquisitions include approximately eight industrial injury prevention services businesses Seeking & evaluating M&A transactions is part of USPh’s DNA PT acquisition criteria: Owner therapists continue to operate clinics and retain significant equity interest Immediately accretive to earnings Further de novo growth opportunities High quality clinics with a history of profitability Values Alignment
Page 13
New Clinics Since October 1, 2024 13 99 clinics added (1) since October 1, 2024 From 10/01/2024 – 9/30/2025 WV VT VA SC PA OH NJ NC ME MD MA GA FL CT TX OK MS LA AR AL AK TN 5 (1) Includes de-novo clinics and acquisitions of sin gle and multi-site practices.
Page 14
Scale Advantages Create a Robust Business Case for Consolidation 14 Source: “Industry Trends in M&A and Total Addressable Market Study” (Bain & Company, WebPT) Efficiency More efficient, patient- centric care model -- including clinic, home and telehealth options Compliance Enhanced compliance capabilities Payor Networks Increased likelihood of selection for payor networks Scale is cited as a core criterion by specialty network managers and payors. Ability to negotiate higher rates for reimbursement with commercial payors Referrals Higher likelihood of referrer activity and advocacy Centralization Centralized infrastructure to limit costs and improve operational efficiencies Awareness Increased patient awareness and high brand recognition Increasingly difficult environment for smaller clinics given increasing compliance, regulatory and payor complexities and challenging macroeconomic conditio ns
Page 15
Revenue Mix by Segment and Payor Type 15 49% 3% 33% 10% 5% Physical Therapy Revenue Mix by Payor Type Three Months Ended September 30, 2025 Other Workers Comp Private Insurance & Managed Care Medicaid Medicare 15% 85% Revenue Mix by Segment Type Three Months Ended September 30, 2025 Physical Therapy Operations Industrial Injury Prevention
Page 16
USPh Physical Therapy Growth Drivers 16 431 472 489 508 540 578 591 583 554 591 640 671 722 745 0 100 200 300 400 500 600 700 800 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 23 24 YTD 25 2,314 2,441 2,819 3,080 3,317 3,705 3,958 4,092 3,533 4,220 4,483 5,005 5,353 5,990 0 1,000 2,000 3,000 4,000 5,000 6,000 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 23 24 TTM 25 21.7 21.5 22.9 24.1 25 25.9 26.6 27.6 24.6 29.1 28.7 30.0 30.4 32.0 0 5 10 15 20 25 30 35 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 23 24 YTD 25 (1) In 2019, the Company sold interest in a partners hip, which operated 30 clinics. In 2020, the Company sold 14 previously closed clinics and closed 34 clinics. Number of Owned Clinics (1) Daily Patient Visits Per Clinic Number of Patient Visits (in thousands) Both prior to and post COVID-19, each driver has shown robust growth 2012-2025: CAGR +4% 2012-2025: CAGR +3% 2012-2025: CAGR +8%
Page 17
Daily Physical Therapy Volumes Progression 17 Continue to see record-high volumes Average daily visits per clinic was of 32.2 was a record-high for any third quarter 26.2 18.9 25.8 27.7 27.1 30.0 29.5 29.8 27.9 29.5 28.8 29.1 29.8 30.4 29.7 29.9 29.5 30.6 30.1 31.6 31.2 32.7 32.2 0 5 10 15 20 25 30 35 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 COVID Trough Average Visits per Clinic per Day
Page 18
Physical Therapy Operations 18 23.6% 23.1% 23.8% 20.6% 20.3% 19.2% 12.0% 14.0% 16.0% 18.0% 20.0% 22.0% 24.0% 26.0% 2019 2020 2021 2022 2023 2024 Note: Excludes management contracts. Also excludes closure costs where applicable. (1) Amortization of certain intangible assets was reallocated between the physical therapy operations and IIP segments. Prior year amounts were reallocated to conform with current presentation. (2) This is a non-GAAP measure. See a reconciliation of GAAP to Non-GAAP financial measures in our filings with the SEC for the periods presented. Annual Gross Margin Percentage (1) 21.4% 21.7% 18.4% 19.9% 18.4% 20.8% 19.2% 18.4% 16.6% 21.2% 18.6% 12.0% 14.0% 16.0% 18.0% 20.0% 22.0% 24.0% 26.0% Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Excludes $3.4M of clinic closure costs (2) Quarterly Adjusted Gross Margin Percentage (1)(2)
Page 19
Today Services performed onsite at >600 client locations Industrial Injury Prevention 19 Industrial Injury Prevention services include industrial sports medicine and injury prevention, post offer testing, ergonomic services, occupational health and medical services, and specialized solutions March 2017 2020 14.8% of Total Revenue (3) Since USPh’s initial entry into the Industrial Injury Prevention services space, the business has grown both organically and through additional acquisitions (1) % of Revenue full year 2018. (2) % of Revenue full year 2020. (3) Revenue for the year-to-date ended September 30, 2025. 5.6% of Total Revenue (1) 9.3% of Total Revenue (2) Initial Acquisition into the Industrial Injury Prevention services space 2018
Page 20
Industrial Injury Prevention 20 20.4% 22.4% 24.7% 23.1% 18.2% 18.5% 18.6% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 2018 2019 2020 2021 2022 2023 2024 $25.5 $37.5 $39.2 $43.9 $77.1 $78.3 $96.9 $0.0 $20.0 $40.0 $60.0 $80.0 $100.0 2018 2019 2020 2021 2022 2023 2024 Note: (1) Amortization of certain intangible assets was reallocated between the physical therapy operations and IIP segments. Prior year amounts were reallocated to conform with current presentation. (2) 2022 includes November 2021 acquisition with $26.7 million in revenue at an EBITDA Margin of 16.0%. Revenue ($ in millions) Gross Margin (%) (1) Third Quarter 2025 : Revenue +14.6% Gross profit +15.6% Gross Margin 19.6% TTM Revenue through Q3 2025: $112.1 million
Page 21
Strong Balance Sheet and Capital Allocation Strategy 21 A strong balance sheet and capital allocation strategy has allowed USPH to return value to shareholders both directly and through strategic growth investments 31.1 $148.5 Liquidity Cash Revolver Capacity Acquisitions Continue fueling a highly acquisitive growth strategy within a fragmented landscape Maintain strategic flexibility and a conservative balance sheet Debt Management Capital Allocation Strategy Liquidity ($ in millions) (as of 9/30/2025) Dividend Payments History of dividend increases and the ability to return value to shareholders directly De Novos Develop de novo physical therapy clinics, increase industrial injury locations and add services in both businesses Share Repurchase Authorization to repurchase up to $25M if market conditions are appropriate.
Page 22
Executive Management 22 Joined USPh as CFO in November 2020 Previously served as CFO for Capital Senior Living Corporation (NYSE:CSU) and Belo Corp. (NYSE: BLC) BBA & MBA Carey Hendrickson Chief Financial Officer Joined USPh in March 2018 Previously President & Chief Executive Officer of Baptist Health System in San Antonio, TX. Managed six hospitals with a $1.32B annual operating budget BS Physical Therapy & MBA Graham Reeve Chief Operating Officer – West Region Joined USPh in July 2021 Served since August 2018 as President and Chief Operating Officer for Omni Ophthalmic Management Consultants (OOMC), an ophthalmology management services organization Previously served in the roles of Chief Operating Officer and then Chief Executive Officer of Drayer Physical Therapy Institute, LLC, an outpatient physical therapy provider with a network of over 150 clinics in 14 states BA in Materials and Logistics Management Eric Williams President, Chief Operating Officer – East Region Joined USPh in May 2011 as VP, General Counsel and Secretary Promoted to EVP General Counsel in March 2022 Previously served as VP, General Counsel and Secretary for Physiotherapy Associates, Inc. (and its predecessor, Benchmark Medical, Inc.), a national provider of outpatient physical therapy services. From 1997 through 2000, served as Assistant General Counsel and then General Counsel of NovaCare, Inc., a national provider of rehabilitation services. Law degree from The Columbus School of Law at The Catholic University of America and Bachelor of Science degree in Business Administration from the University of Delaware in 1983 Rick Binstein Executive VP & General Counsel Joined USPh as COO in November 2003 Promoted to CEO and Board in November 2004 Previously Senior Vice President of Operations with HealthSouth, managed over 200 facilities including OP, ASC, DX Imaging and rehab hospital operations BS Physical Therapy Chris Reading Chief Executive Officer
Page 23
23 Summary Investment Highlights Significant scale with national footprint Large and growing market / favorable demographics Proven business model, driven by organic growth and acquisitions Strong cash flow and balance sheet Publicly-traded, pure play operator of rehab clinics Attractive Dividend Yield
Page 24
APPENDIX
Page 25
Demonstrated Track Record of Consistent Growth Over the last decade, USPH has consistently grown, organically and through strategic acquisitions $264 $305 $331 $357 $414 $454 $482 $423 $495 $553 $605 $671 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 23 24 $35 $46 $50 $54 $58 $62 $67 $57 $74 $74 $78 $82 13 14 15 16 17 18 '19 '20 '21 '22 23 24 USPH Revenue ($ in millions) Adj. EBITDA (1) ($ in millions) 4.7% 15.5% 8.6% 7.6% 16.1% 9.6% 6.2% (12.2%) 17.0% 11.7% 19.2% 21.3% 18.4% 16.8% 25 Growth (%) Margin (%) 2013-2024: CAGR +8% 2013-2024: CAGR +9% (1) Adjusted EBITDA and Adjusted EBITDA margin are n on-GAAP financial measures and have not been prepared in accordance with GAAP. See Reconciliation of Non-GAAP Financial Measures - Adjusted EBITDA and Adjusted EBITDA margin for further detail. 9.4% 15.9% 11.0% 15.2% Adjusted EBITDA Margin Q3 2025 – 15.5% and Q3 2024 – 15.5%
Page 26
Summary Financial Results 26 (1) Operating Results, a non-GAAP measure, equals ne t income attributable to our shareholders less, changes in revaluation of a put-right liability, clinic closure costs, loss on sale of a partnership, changes in fair value of contingent earn-out consideration, business acquisition related costs, costs related to a one-time financial systems upgrade, non-recurring or any other one-time expenses and the associated allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact. (2) Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to our shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs, costs related to a one-time financial systems upgrade, loss on sale of a partnership and other income, non-recurring or any other one-time expenses and the related portions for non-controlling interests. September 30, 2025 September 30, 2024 September 30, 2 025 September 30, 2024 Net Revenue 197,132 $ 168,033 $ 578,264 $ 490,898 $ Operating costs 160,260 13 8,902 468,703 399,504 Gross profit 36,872 29,1 31 109,561 91,394 Operating income 25,330 12,847 69,910 43,343 Net income 17,642 9,77 7 48,830 33,106 Net Income attributable to USPH shareholders 13,138 6,628 35,430 22, 180 Non-GAAP Operating results (1) 10,071 10,386 29,733 29,162 Non-Gaap Operating results per share (1) 0.66 0.69 1.96 1.94 Non-GAAP Adjusted EBITDA (2) 23,855 $ 21,071 70,256 59,966 $ Three Months Ended Nine Months Ended (in thousands, except per share data)
Page 27
Segment Information 27 (1) Amortization of certain intangible assets was reallocated between the physical therapy operations and IIP segments. Prior year amounts were reallocated to conform with current presentation. (2) Certain incentive costs related to the Metro acquisition and gains or losses related to clinic closures, as applicable. (3) Costs associated with the closure of 13 owned clinics during the 2025 Nine Months and 43 owned clinics during the 2024 Nine Months. Reported Adjustments Adjusted Reported Adjustments Adjus ted Physical Therapy Operations Net Revenue 168,110 $ 168,110 $ 142,714 $ 142,714 $ Gross profit (1) 31,193 (50) (2) 31,143 23,999 3,432 (3) 27,431 Gross margin (1) 18.6% 18.6% 16.8% 19.2% Net revenue, excluding management contracts 165,660 $ 165,660 $ 140,172 $ 140,172 $ Gross profit, excluding management contracts 30,681 30,681 23,474 23,474 Gross margin, excluding management contracts 18.5% 18.5% 16.7% 16.7% IIP Net Revenue 29,022 $ 29,022 $ 25,319 $ 25,319 $ Gross profit (1) 5,679 5,679 5,1 32 5,132 Gross margin (1) 19.6% 19.6% 20.3% 20.3% Operating income 25,330 $ (50) $ (2) 25,280 12,847 $ 3,432 (3) 16,279 Operating income margin 15.1% 15.0% 9.0% 11.4% Reported Adjustments Adjusted Reported Adjustments Adjus ted Physical Therapy Operations Net Revenue 492,810 $ 492,810 $ 420,625 $ 420,625 $ Gross profit (1) 92,877 555 (2) 93,432 77,829 4,109 (3) 81,938 Gross margin (1) 18.8% 19.0% 18.5% 19.5% Net revenue, excluding management contracts 485,548 $ 485,548 $ 413,285 $ 413,285 $ Gross profit, excluding management contracts 91,488 91,488 76,368 76,368 Gross margin, excluding management contracts 18.8% 18.8% 18.5% 18.5% IIP Net Revenue 85,454 $ 85,454 $ 70,273 $ 70,273 $ Gross profit (1) 16,684 16,684 13,56 5 13,565 Gross margin (1) 19.5% 19.5% 19.3% 19.3% Operating income 69,910 $ 555 70,465 $ 43 ,343 $ 4,109 (3) 47,452 $ Operating income margin 14.2% 14.3% 10.3% 11.3% Three Months Ended September 30, 2025 Three Months E nded September 30, 2024 NIne Months Ended September 30, 2025 NIne Months End ed September 30, 2024 (in thousands, except percentages) (in thousands, except percentages)
Page 28
Reconciliation of Non-GAAP Financial Measures – Operating Results 28 (1) Costs associated with the closure of 13 owned clinics during the 2025 Nine Months and 43 owned clinics during the 2024 Nine Months.. (2) Primarily consists of retention bonuses, legal and consulting expenses related to the acquisitions of equity interests in certain partnerships. (3) Consists of costs related to a one-time financial and human resources systems upgrade. . September 30, 2025 September 30, 2024 September 30, 2 025 September 30, 2024 Operating Results (a non-GAAP measure) Net income attributable to USPH shareholders 13,1 38 $ 6,628 $ 35,430 $ 22,180 $ Adjustments: (Gain) loss on change in fair value of contingent earn-out consideration (5,872) 1,899 (11,484) 5,332 Change in revaluation of put-right liability 6 63 (168) 1,406 136 Clinic closure costs (1) (42) 3,432 269 4,109 Business acquisition related costs (2) 70 314 870 314 ERP implementation costs (3) 664 - 885 - Loss on sale of a partnership - - 123 - Allocation to non-controlling interests 397 (429) 279 (513) Tax effect at statutory rate (federal and state) 1,053 (1,290) 1,955 (2,39 6) 10,071 $ 10,386 $ 29,733 $ 29,162 $ Operating Results per share (a non-GAAP measure) 0.6 6 $ 0.69 $ 1.96 $ 1.94 $ Nine Months Ended Three Months Ended (In thousands, except per share data)
Page 29
Reconciliation of Non-GAAP Financial Measures Adjusted EBITDA and Adjusted EBITDA Margin 29 September 30, 2025 September 30, 2024 September 30, 2 025 September 30, 2024 Adjusted EBITDA (a non-GAAP measure) Net income attributable to USPH shareholders 13,1 38 $ 6,628 $ 35,430 $ 22, 180 $ Adjustments: Provision for income taxes 5,233 2,559 14,0 26 8,781 Depreciation and amortization 5,832 4,387 1 7,756 12,996 Interest expense, debt and other, net 2,408 2,018 7,109 5,966 Equity-based awards compensation expense 2,263 1,921 6,151 5,837 Interest income from investments (33) (1,018) (85) (3,6 35) Change in revaluation of put-right liability 663 (168) 1,406 136 (Gain) loss on change in fair value of contingent earn-out consideration (5,872) 1,899 (11,484) 5,332 Clinic Closure costs (1) (42) 3,432 26 9 4,109 Business acquisition related costs (2) 70 314 870 314 ERP implementation costs (3) 664 - 885 - Loss on sale of a partnership - - 123 - Other income (222) ( 90) (344) (261) Allocation to non-controlling interests (247) (811) (1,856) ( 1,789) 23,855 $ 21,071 $ 70,256 $ 59,966 $ Net revenue, as reported 197,132 168,033 578,264 490,898 Minority interest (42,941) (32,464) (124,697) (93,712) Net revenue after minority interest 154,191 $ 135,569 $ 4 53,567 $ 397,186 $ Adjusted EBITDA margin (a non-GAAP measure) 15.5% 15. 5% 15.5% 15.1% Nine Months Ended Three Months Ended (In thousands, except per share data) (1) Costs associated with the closure of 13 owned clinics during the 2025 Nine Months and 43 owned clinics during the 2024 Nine Months.. (2) Primarily consists of retention bonuses, legal and consulting expenses related to the acquisitions of equity interests in certain partnerships. (3) Consists of costs related to a one-time financial and human resources systems upgrade. .
Page 30
30 Thank you